New Nanoparticle Treatment for Abdominal Aortic Aneurysm
Development of phospholipid-based nanotherapeutics for treating abdominal aortic aneurysm
This research explores a new way to deliver anti-inflammatory medicine using tiny particles to help patients with abdominal aortic aneurysms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11090423 on NIH RePORTER |
What this research studies
Abdominal aortic aneurysm (AAA) is a serious condition where the main artery in your belly bulges, and it can be life-threatening if it ruptures. Currently, surgery is the only effective treatment for large aneurysms, but many smaller aneurysms grow over time and eventually need surgery. There isn't a good medicine right now to stop these smaller aneurysms from growing. This project aims to create a new medical treatment using special nanoparticles that can target the aneurysm directly. These nanoparticles would deliver anti-inflammatory agents to reduce swelling and improve the health of the artery wall, potentially preventing the aneurysm from getting bigger.
Who could benefit from this research
Good fit: This research is most relevant for adult patients aged 21 and older who have been diagnosed with a small abdominal aortic aneurysm that does not yet require surgical repair.
Not a fit: Patients with large or symptomatic abdominal aortic aneurysms that already require immediate surgical intervention may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this new treatment could offer a non-surgical option to slow or stop the growth of abdominal aortic aneurysms, reducing the risk of rupture for many patients.
How similar studies have performed: While previous anti-inflammatory drugs have not shown success in clinical trials for AAA, studies in animal models have shown that reducing inflammation can effectively slow aneurysm progression, and this project introduces a novel nanoparticle delivery strategy.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Guo, Yanhong — University of Michigan at Ann Arbor
- Study coordinator: Guo, Yanhong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.